Self-report data as a tool for subtype identification in genetically-defined Parkinson's Disease.

Sci Rep

Neuroscience, Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA.

Published: August 2018


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Through a targeted recruitment 23andMe has collected DNA and patient-reported symptoms from more than 10,000 subjects reporting a physician-verified diagnosis of PD. This study evaluated the potential of self-report, web-based questionnaires to rapidly assess disease natural history and symptomology in genetically-defined PD populations. While average age-at-diagnosis was significantly lower in GBA mutation carriers compared to idiopathic PD, or iPD (idiopathic PD, defined as no GBA mutations and no LRRK2 G2019S mutation), there were no significant differences in symptoms. Conversely, LRRK2 G2019S carrier status significantly associated with reporting of milder daily symptoms of lightheadedness and several differences were observed at a false discovery rate < 0.1, including increased reporting of changes in walking as an initial symptom of disease, decreased reporting of lightheadedness upon standing, and milder symptoms related to daily functioning. The subclinical differences in symptoms reported by LRRK2 G2019S carriers suggest differences in underlying pathophysiology and/or disease progression in LRRK2 carriers compared to iPD. Importantly, we confirm previous findings in PD genetic subsets where disease characteristics were ascertained through clinical exam. Overall, these data support the effective use of self-report and genetic data to rapidly analyze information from a large disease population or difficult to identify genetic subgroups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113219PMC
http://dx.doi.org/10.1038/s41598-018-30843-6DOI Listing

Publication Analysis

Top Keywords

lrrk2 g2019s
8
self-report data
4
data tool
4
tool subtype
4
subtype identification
4
identification genetically-defined
4
genetically-defined parkinson's
4
parkinson's disease
4
disease targeted
4
targeted recruitment
4

Similar Publications

Objective: To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.

View Article and Find Full Text PDF

Parkinson's Disease (PD) is a neurodegenerative disorder often preceded by gastrointestinal dysfunction. Mutations in leucine-rich repeat kinase 2 (LRRK2) are known risk factors for both PD and inflammatory bowel disease (IBD), suggesting a link between PD and the gastrointestinal tract. Using single-cell RNA-sequencing and spectral flow cytometry, we demonstrated that the Lrrk2 Gly2019Ser (G2019S) mutation is associated with an increased neutrophil presence in the colonic lamina propria during Citrobacter rodentium infection.

View Article and Find Full Text PDF

Comparative Molecular Dynamics Reveals How LRRK2 Inhibitors Distinguish G2019S from Wild-Type.

Neurochem Res

August 2025

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.

Leucine-rich repeat kinase 2 (LRRK2) has become a critical drug target in Parkinson's disease, with mutation-selective inhibitors offering promising potential for precision medicine. However, the structural similarity between G2019S and wild-type kinases presents a significant challenge in developing selective inhibitors. Although recent advances have led to inhibitors that selectively target G2019S or wild-type kinases, the selectivity mechanism of these inhibitors remains unclear.

View Article and Find Full Text PDF

Background: Interest in Parkinson's disease (PD) prevention trials is growing, and genetically at-risk individuals may be ideal candidates. LRRK2 G2019S is the most common autosomal dominant genetic cause of PD and exhibits incomplete penetrance.

Objective: In a remote, prospective cohort study of LRRK2 G2019S carriers without PD, we examined change over time to better understand the natural history of LRRK2 PD.

View Article and Find Full Text PDF

Ergothioneine (ET) is a naturally occurring thiol/thione that possesses several cytoprotective properties. Multiple studies suggest a potential neuroprotective role for ET. Here, we show in various Parkinson's disease (PD) models that ET is indeed neuroprotective.

View Article and Find Full Text PDF